23andMe Holding Co. (NASDAQ: ME), the genetic screening company that went public via a SPAC in 2021, received a deficiency letter from the Nasdaq, warning the firm that it could be delisted if it does not find a way to bump the price of its stock over a dollar.
The letter sent on Nov. 10 warns from the Nasdaq Listing Qualifications department, warned that 23andMe is not compliance with exchange regulations that require listed stocks maintain a minimum bid price of $1 per share, and that it fell…
Source link
